https://www.selleckchem.com/sc....reening/kinase-inhib
The patient achieved molecular remission 3 months after imatinib therapy. The present study indicates Nanopore sequencing as a valid strategy, which can characterize breakpoints precisely in special clinical cases with atypical structural variations. CML patients with e14a3 transcripts may have good clinical course in the tyrosine kinase inhibitor era, as reviewed here. The present study indicates Nanopore sequencing as a valid strategy, which can characterize breakpoints precisely in special clinical cases with atypic
Like
Comment
Share
